INFERNO Stack: Patient Information & Safety Notes
Also known as INFERNO peptide blend
Other names: inferno-peptide-blend
INFERNO is a proprietary injectable blend of AOD-9604, CJC-1295, Ipamorelin, and MOTS-C. None of the individual components are FDA-approved for the promoted uses, and the combination has not been studied in human trials.
In plain language
What AOD-9604 / CJC-1295 / Ipamorelin / MOTS-C Blend is used for
- Marketed for metabolic and performance goals, but safety and benefit of the combination are unknown
Taking this medicine
How it is administered
- Subcutaneous injection
What's in it
Ingredients
Read before you decide
Risks and precautions
Risks and warnings
- Injection site irritation, flushing
- Nausea
- Cumulative risks of component compounds
Who should not take it
- Pregnancy
- History of cancer
Common questions
Patient questions
Is INFERNO an FDA-approved treatment?
No. INFERNO is a proprietary compounded blend of research compounds. It is not FDA-approved. Availability is specific to the prescribing context.
Related medications
Explore treatment hubs
This information is educational — not medical advice.
This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.
Sources & References
Learn more about where our data comes from and how we write and review medical content.